Proteomics reveals MRPL4 as a high‐risk factor and a potential diagnostic biomarker for prostate cancer

Fu, Qihuan; Hong, Ruixia; Zhou, Hang; Liu, Ying; Liu, Xiu; Gong, Jiaqi; Wang, Xiaoyang; Chen, Jiajia; Ran, Haiying; Wang, Liting; Li, Fang; Yuan, Jiangbei

doi:10.1002/pmic.202200081

Cited by 7 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MRPL4 has been identified as a high-risk factor for prostate cancer (PC) and a potential diagnostic biomarker. 39 Additionally, MRPS12 has been implicated in ovarian cancer. 40 Several reports indicate that POLR2L plays a significant role in PC, glioblastoma (GBM), and HBV-related hepatocellular carcinoma (HCC).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Dual-Specificity Phosphatase 23 Expression in Acute Myeloid Leukemia

Liu,

Zhuang,

et al. 2024

JBM

View full text Add to dashboard Cite

Background Recently, an increasing number of studies have suggested dual-specificity phosphatase 23 (DUSP23) is a critical factor in the development of diffuse connective tissue disease and may be a valuable biomarker for primary human cancers. However, there is a lack of comprehensive studies on the prognostic significance of DUSP23 expression in acute myeloid leukemia (AML). Methods RNA sequencing data from The Cancer Genome Atlas (TCGA) (AML = 173), Genotype-Tissue Expression (GTEx) (healthy controls = 70) and GEO (AML = 461, healthy controls = 76) databases were used to compare DUSP23 expression between AML patients and healthy controls. The overall survival (OS) of DUSP23 in AML was evaluated using Kaplan-Meier Cox regression. Furthermore, univariate Cox regression and multivariate Cox regression analysis were used to determine whether DUSP23 was an independent prognostic factor for AML. We then verified the expression level and prognostic significance of DUSP23 in our cohort (AML = 128, healthy controls = 31). In addition, functional enrichment analysis of DUSP23-related DEGs was performed through gene set enrichment analysis (GSEA) and protein-protein interaction (PPI) network analysis. Results The expression level of DUSP23 is significantly higher in AML patients than in healthy controls in TCGA, GTEx, GEO databases and our cohort. By multivariate analysis, high expression of DUSP23 is a poor prognostic indicator of OS in the TCGA database. Next, we verified the role of DUSP23 as an adverse prognostic biomarker in our cohort. Enrichment analysis of related genes showed that DUSP23 may regulate important signal pathways in hematological tumors including the MAPK pathways. It is suggested by the PPI network that DUSP23, along with IMP3, MRPL4, MRPS12, POLR2L, and ATP5F1D may play a role in the process of AML. Conclusion The study demonstrated high expression of DUSP23 could serve as a poor independent prognostic biomarker in AML.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Dual-Specificity Phosphatase 23 Expression in Acute Myeloid Leukemia

Liu,

Zhuang,

et al. 2024

JBM

View full text Add to dashboard Cite

show abstract

“…As prostate cancer progresses to an advanced stage of metastasis, there is a more substantial alteration in the proteomic changes reflecting cell cycle and DNA damage [ 13 , 14 ]. Several studies have identified protein markers that promote prostate cancer metastasis using proteomics techniques [ 15 , 16 ]. However, molecular markers that accurately predict metastatic risk are still lacking.…”

Section: Introductionmentioning

confidence: 99%

Radiogenomic analysis of ultrasound phenotypic features coupled to proteomes predicts metastatic risk in primary prostate cancer

Fu,

Luo,

Hong

et al. 2024

BMC Cancer

Self Cite

View full text Add to dashboard Cite

Background Primary prostate cancer with metastasis has a poor prognosis, so assessing its risk of metastasis is essential. Methods This study combined comprehensive ultrasound features with tissue proteomic analysis to obtain biomarkers and practical diagnostic image features that signify prostate cancer metastasis. Results In this study, 17 ultrasound image features of benign prostatic hyperplasia (BPH), primary prostate cancer without metastasis (PPCWOM), and primary prostate cancer with metastasis (PPCWM) were comprehensively analyzed and combined with the corresponding tissue proteome data to perform weighted gene co-expression network analysis (WGCNA), which resulted in two modules highly correlated with the ultrasound phenotype. We screened proteins with temporal expression trends based on the progression of the disease from BPH to PPCWOM and ultimately to PPCWM from two modules and obtained a protein that can promote prostate cancer metastasis. Subsequently, four ultrasound image features significantly associated with the metastatic biomarker HNRNPC (Heterogeneous nuclear ribonucleoprotein C) were identified by analyzing the correlation between the protein and ultrasound image features. The biomarker HNRNPC showed a significant difference in the five-year survival rate of prostate cancer patients (p < 0.0053). On the other hand, we validated the diagnostic efficiency of the four ultrasound image features in clinical data from 112 patients with PPCWOM and 150 patients with PPCWM, obtaining a combined diagnostic AUC of 0.904. In summary, using ultrasound imaging features for predicting whether prostate cancer is metastatic has many applications. Conclusion The above study reveals noninvasive ultrasound image biomarkers and their underlying biological significance, which provide a basis for early diagnosis, treatment, and prognosis of primary prostate cancer with metastasis.

show abstract

“…Deep mining of the cancer proteome could help to understand the mechanism of tumorigenesis and discover novel biomarkers or potential therapeutic targets. In PCa, proteomics was applied to discover biomarkers [ 4 – 6 ], key proteins in PCa progression [ 7 , 8 ], or protein interaction networks [ 9 , 10 ]. In recent years, the application of 4-dimensional proteomics has provided a promising tool to identify more proteins with lower abundance due to its high sensitivity, compared with traditional 3D proteomics [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Proteomic profiling of prostate cancer reveals molecular signatures under antiandrogen treatment

Huang,

Yang,

Yao

et al. 2024

Clin Proteom

View full text Add to dashboard Cite

Background Tumorigenesis and progression of prostate cancer (PCa) are indispensably dependent on androgen receptor (AR). Antiandrogen treatment is the principal preference for patients with advanced PCa. However, the molecular characteristics of PCa with antiandrogen intervention have not yet been fully uncovered. Methods We first performed proteome analysis with 32 PCa tumor samples and 10 adjacent tissues using data-independent acquisition (DIA)- parallel accumulation serial fragmentation (PASEF) proteomics. Then label-free quantification (LFQ) mass spectrometry was employed to analyze protein profiles in LNCaP and PC3 cells. Results M-type creatine kinase CKM and cartilage oligomeric matrix protein COMP were demonstrated to have the potential to be diagnostic biomarkers for PCa at both mRNA and protein levels. Several E3 ubiquitin ligases and deubiquitinating enzymes (DUBs) were significantly altered in PCa and PCa cells under enzalutamide treatment, and these proteins might reprogram proteostasis at protein levels in PCa. Finally, we discovered 127 significantly varied proteins in PCa samples with antiandrogen therapy and further uncovered 4 proteins in LNCaP cells upon enzalutamide treatment. Conclusions Our research reveals new potential diagnostic biomarkers for prostate cancer and might help resensitize resistance to antiandrogen therapy.

show abstract

Proteomics reveals MRPL4 as a high‐risk factor and a potential diagnostic biomarker for prostate cancer

Cited by 7 publications

References 31 publications

Prognostic Significance of Dual-Specificity Phosphatase 23 Expression in Acute Myeloid Leukemia

Prognostic Significance of Dual-Specificity Phosphatase 23 Expression in Acute Myeloid Leukemia

Radiogenomic analysis of ultrasound phenotypic features coupled to proteomes predicts metastatic risk in primary prostate cancer

Proteomic profiling of prostate cancer reveals molecular signatures under antiandrogen treatment

Contact Info

Product

Resources

About